Navigation Links
Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
Date:9/9/2008

NEW HAVEN, Conn., Sept. 9 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, announced today the formation of its Clinical Advisory Board. The Board, comprised of six infectious disease specialists, will provide oversight and counsel on matters related to the Company's clinical development programs.

Dr. Robert C. Moellering, Jr., M.D., will serve as Chairman of the Clinical Advisory Board. From 1999 to 2005, Dr. Moellering was the Herrman L. Blumgart Professor of Medicine at Harvard Medical School and Chairman of the Department of Medicine at Beth Israel Deaconess Medical Center, Boston. He now holds the Shields Warren-Mallinckrodt Chair of Medical Research at Harvard Medical School, and was the founder and served as the CEO of the Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center until 2004.

Other individuals named to the Advisory Board include:

-- Helen W. Boucher, M.D., Assistant Professor of Medicine, Tufts University School of Medicine, Director of the Infectious Diseases Fellowship Program, and Staff Physician in the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center, Boston;

-- Henry F. Chambers, M.D., Chief Professor of Medicine in the Division of Infectious Diseases at San Francisco General Hospital, and the Director of the University of California, San Francisco Infectious Diseases Fellowship Training Program;

-- Barbara E. Murray, M.D., Director of the Division of Infectious Diseases at the University of Texas-Houston Medical School, and Co-Director of the UTHSC-H Center for the Study of Emerging and Re-Emerging Pathogens;

-- Leon G. Smith, M.D., Professor of Medicine and Preventive Medicine / Community Health at the University of Medicine and Dentistry of New Jersey, Chair of the Residency Program in Internal Medicine at Seton Hall University School of Graduate Medical Education, and the Director of Medicine and Chief of Infectious Disease at St. Michael's Medical Center;

-- Richard P. Wenzel, M.D., M.Sc., Professor and Chairman of the Department of Internal Medicine, Senior Associate Dean for Clinical Affairs, and President of MCV Physicians at the Medical College of Virginia/Virginia Commonwealth University in Richmond, Virginia.

"This world-class Advisory Board was attracted to the Rib-X mission of discovering and developing new therapies for life-threatening, resistant bacterial infections, and we are proud to have them as colleagues and advisors at this important time in our growth," said Susan Froshauer, Ph.D, President and CEO of Rib-X. "The formation of the Clinical Advisory Board is indicative of our evolution as a Company and we look forward to working with these board members to advance our clinical programs."

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. Radezolid (RX-1741), an oxazolidinone, is an oral/IV agent for treatment of serious Gram-positive infections. The RX-04 discovery program is developing novel classes of antibiotics active against multi-drug resistant Gram-negative bacteria and the RX-02 discovery program is focused on developing an IV/oral macrolide active against methicillin-resistant Staphylococcus aureus, multidrug-resistant Streptococci pneumonia and S. pyogenes. Additionally, Rib-X is developing delafloxacin, (RX-3341), an anionic fluoroquinolone active against a broad spectrum of bacteria, including quinolone resistant Gram positive bacteria and MRSA. Both radezolid and delafloxacin are currently in Phase 2 clinical trials.

For more information on the ribosome and the Rib-X mission, please visit the Company website at http://www.rib-x.com.


'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
2. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
3. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
5. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
6. VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC
7. Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management
8. Alseres Pharmaceuticals, Inc. Raises $5 Million
9. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
10. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
11. Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... and LONDON , May 23, 2016 /PRNewswire/ ... See Frontage Boost Efficiency by 40% - Frontage Implement ... - Frontage Enforce Quality, Compliance and Traceability Within the Bioanalytical lab ... labs in the United States and ... to be deployed across its laboratory facilities. In addition to serving ...
(Date:5/20/2016)... (PRWEB) , ... May 20, 2016 , ... The leading ... of its most experienced veterinary clients have treated over 100 of their own patients ... technology to provide the highest level of care for their patients. , The ...
(Date:5/19/2016)... (PRWEB) , ... May 19, 2016 , ... Anton Paar ... 30,000 square foot office building is complete. The new structure adds a third office ... Anton Paar USA purchased 2.4 acres of land, along with office space ...
(Date:5/19/2016)... DIEGO , May 19, 2016 ... (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today ... creating the first cord blood based cancer immunotherapeutic ... provisional patent application, Regen described a generation of ... was potentiated by gene silencing.  The product in ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
Breaking Biology News(10 mins):